Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Acceleron Pharma Inc (XLRN) since 2014 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Acceleron Pharma Inc. Table 2 shows the detailed insider transactions. This company's CIK number is 1280600.
Total stock buying since 2014: $100,246,002.
Total stock sales since 2014: $198,091,133.
Total stock option exercises since 2014: $24,620,985.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2021 | 0 | $0 | 209,945 | $28,478,243 | 189,000 | $6,694,568 |
| 2020 | 108,108 | $9,999,990 | 241,955 | $24,339,499 | 239,522 | $7,422,092 |
| 2019 | 711,206 | $30,557,108 | 121,332 | $5,293,708 | 46,408 | $1,076,480 |
| 2018 | 0 | $0 | 147,714 | $6,650,914 | 117,251 | $1,560,589 |
| 2017 | 745,592 | $27,586,904 | 238,050 | $8,422,804 | 60,663 | $588,906 |
| 2016 | 804,000 | $32,102,000 | 1,932,594 | $68,877,711 | 747,631 | $4,143,811 |
| 2015 | 0 | $0 | 863,759 | $27,950,120 | 461,774 | $1,789,745 |
| 2014 | 0 | $0 | 805,425 | $28,078,134 | 406,392 | $1,344,794 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2021-11 | 0 | $0 | 0 | $0 | 4,500 | $132,165 |
| 2021-09 | 0 | $0 | 43,063 | $6,823,630 | 41,650 | $1,599,840 |
| 2021-07 | 0 | $0 | 100,000 | $12,714,276 | 100,000 | $3,503,999 |
| 2021-04 | 0 | $0 | 40,789 | $5,643,222 | 37,850 | $1,255,514 |
| 2021-03 | 0 | $0 | 5,000 | $683,740 | 5,000 | $203,050 |
| 2021-01 | 0 | $0 | 21,093 | $2,613,375 | 0 | $0 |
| 2020-12 | 0 | $0 | 50,000 | $6,468,769 | 50,000 | $1,768,656 |
| 2020-10 | 0 | $0 | 37,500 | $4,474,500 | 37,500 | $1,081,387 |
| 2020-09 | 0 | $0 | 25,272 | $2,289,052 | 23,272 | $734,813 |
| 2020-07 | 108,108 | $9,999,990 | 52,241 | $5,056,009 | 50,000 | $1,752,000 |
| 2020-04 | 0 | $0 | 60,000 | $5,167,789 | 60,000 | $2,012,486 |
| 2020-01 | 0 | $0 | 16,942 | $883,380 | 18,750 | $72,750 |
| 2019-12 | 0 | $0 | 11,853 | $595,968 | 0 | $0 |
| 2019-09 | 0 | $0 | 21,422 | $972,616 | 0 | $0 |
| 2019-08 | 0 | $0 | 3,268 | $147,060 | 0 | $0 |
| 2019-07 | 0 | $0 | 538 | $21,901 | 8,908 | $48,343 |
| 2019-06 | 5,000 | $190,250 | 37,500 | $1,492,242 | 37,500 | $1,028,137 |
| 2019-04 | 0 | $0 | 27,352 | $1,229,801 | 0 | $0 |
| 2019-01 | 706,206 | $30,366,858 | 19,399 | $834,120 | 0 | $0 |
| 2018-12 | 0 | $0 | 12,675 | $672,535 | 0 | $0 |
| 2018-08 | 0 | $0 | 12,500 | $675,000 | 12,500 | $349,625 |
| 2018-06 | 0 | $0 | 25,000 | $1,200,000 | 25,000 | $602,750 |
| 2018-04 | 0 | $0 | 14,507 | $560,976 | 0 | $0 |
| 2018-03 | 0 | $0 | 37,500 | $1,568,625 | 56,250 | $285,750 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-11-09 | Veness Adam M (SVP, General Counsel and Sec.) | Option Ex | 4,500 | 29.37 | 132,165 |
| 2021-09-27 | Kango Sujay (EVP, Chief Commercial Officer) | Sale | 5,000 | 175.00 | 875,000 |
| 2021-09-27 | Kango Sujay (EVP, Chief Commercial Officer) | Option Ex | 5,000 | 40.61 | 203,050 |
| 2021-09-24 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 5,370 | 160.38 | 861,240 |
| 2021-09-24 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Option Ex | 5,370 | 41.12 | 220,841 |
| 2021-09-23 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 19,630 | 160.76 | 3,155,718 |
| 2021-09-23 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Option Ex | 19,630 | 37.47 | 735,594 |
| 2021-09-21 | Veness Adam M (SVP, General Counsel and Sec.) | Sale | 6,650 | 150.05 | 997,832 |
| 2021-09-21 | Veness Adam M (SVP, General Counsel and Sec.) | Option Ex | 6,650 | 35.69 | 237,305 |
| 2021-09-21 | Kango Sujay (EVP, Chief Commercial Officer) | Sale | 5,000 | 150.03 | 750,150 |
| 2021-09-21 | Kango Sujay (EVP, Chief Commercial Officer) | Option Ex | 5,000 | 40.61 | 203,050 |
| 2021-09-09 | Veness Adam M (SVP, General Counsel and Sec.) | Sale | 1,407 | 130.00 | 182,910 |
| 2021-09-08 | Veness Adam M (SVP, General Counsel and Sec.) | Sale | 6 | 130.00 | 780 |
| 2021-07-02 | Dable Habib J (CEO and President) | Sale | 42,186 | 127.47 | 5,377,449 |
| 2021-07-02 | Dable Habib J (CEO and President) | Option Ex | 42,186 | 35.04 | 1,478,197 |
| 2021-07-01 | Dable Habib J (CEO and President) | Sale | 57,814 | 126.90 | 7,336,827 |
| 2021-07-01 | Dable Habib J (CEO and President) | Option Ex | 57,814 | 35.04 | 2,025,802 |
| 2021-04-05 | Smith Karen L. | Sale | 11,864 | 140.64 | 1,668,552 |
| 2021-04-05 | Smith Karen L. | Option Ex | 8,925 | 43.32 | 386,657 |
| 2021-04-05 | Zakrzewski Joseph S | Sale | 10,000 | 141.29 | 1,412,870 |
| 2021-04-05 | Zakrzewski Joseph S | Option Ex | 10,000 | 24.11 | 241,100 |
| 2021-04-01 | Smith Karen L. | Sale | 8,925 | 136.40 | 1,217,370 |
| 2021-04-01 | Smith Karen L. | Option Ex | 8,925 | 43.32 | 386,657 |
| 2021-04-01 | Zakrzewski Joseph S | Sale | 10,000 | 134.44 | 1,344,430 |
| 2021-04-01 | Zakrzewski Joseph S | Option Ex | 10,000 | 24.11 | 241,100 |
| 2021-03-02 | Kango Sujay (EVP, Chief Commercial Officer) | Sale | 5,000 | 136.75 | 683,740 |
| 2021-03-02 | Kango Sujay (EVP, Chief Commercial Officer) | Option Ex | 5,000 | 40.61 | 203,050 |
| 2021-01-05 | Veness Adam M (SVP, General Counsel and Sec.) | Sale | 2,056 | 123.23 | 253,360 |
| 2021-01-05 | Dable Habib J (CEO and President) | Sale | 4,258 | 121.77 | 518,496 |
| 2021-01-05 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 1,499 | 122.17 | 183,128 |
| 2021-01-04 | Kango Sujay (EVP, Chief Commercial Officer) | Sale | 10,000 | 125.07 | 1,250,730 |
| 2021-01-04 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 3,280 | 124.29 | 407,661 |
| 2020-12-14 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 42,528 | 130.14 | 5,534,593 |
| 2020-12-14 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Option Ex | 42,528 | 34.99 | 1,487,969 |
| 2020-12-11 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 3,100 | 125.00 | 387,500 |
| 2020-12-11 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Option Ex | 3,100 | 41.20 | 127,720 |
| 2020-12-10 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 500 | 125.12 | 62,560 |
| 2020-12-10 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Option Ex | 500 | 34.99 | 17,494 |
| 2020-12-09 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 3,872 | 125.03 | 484,116 |
| 2020-12-09 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Option Ex | 3,872 | 34.99 | 135,473 |
| 2020-10-12 | Kearney Terrence C | Sale | 37,500 | 119.32 | 4,474,500 |
| 2020-10-12 | Kearney Terrence C | Option Ex | 37,500 | 28.84 | 1,081,387 |
| 2020-09-11 | Mccourt Thomas A | Sale | 23,272 | 90.67 | 2,110,002 |
| 2020-09-11 | Mccourt Thomas A | Option Ex | 23,272 | 31.57 | 734,813 |
| 2020-09-08 | Veness Adam M (SVP, General Counsel and Sec.) | Sale | 2,000 | 89.53 | 179,050 |
| 2020-07-09 | Bristol Myers Squibb Co | Sale | 2,241 | 102.28 | 229,209 |
| 2020-07-01 | Dable Habib J (CEO and President) | Sale | 50,000 | 96.54 | 4,826,800 |
| 2020-07-01 | Dable Habib J (CEO and President) | Option Ex | 50,000 | 35.04 | 1,752,000 |
| 2020-07-01 | Bristol Myers Squibb Co | Buy | 108,108 | 92.50 | 9,999,990 |
| 2020-04-09 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 17,226 | 88.19 | 1,519,160 |
| 2020-04-09 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Option Ex | 17,226 | 41.20 | 709,711 |
| 2020-04-08 | Veness Adam M (SVP, General Counsel and Sec.) | Sale | 6,000 | 85.62 | 513,720 |
| 2020-04-08 | Veness Adam M (SVP, General Counsel and Sec.) | Option Ex | 6,000 | 27.97 | 167,820 |
| 2020-04-08 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 36,774 | 85.25 | 3,134,909 |
| 2020-04-08 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Option Ex | 36,774 | 30.86 | 1,134,955 |
| 2020-01-07 | Zakrzewski Joseph S | Option Ex | 18,750 | 3.88 | 72,750 |
| 2020-01-03 | Veness Adam M (VP, General Counsel and Sec.) | Sale | 875 | 51.23 | 44,826 |
| 2020-01-03 | Dable Habib J (CEO and President) | Sale | 3,732 | 51.25 | 191,265 |
| 2020-01-03 | Kango Sujay (SVP, Chief Commercial Officer) | Sale | 480 | 51.32 | 24,633 |
| 2020-01-02 | Veness Adam M (VP, General Counsel and Sec.) | Sale | 434 | 52.83 | 22,928 |
| 2020-01-02 | Quisel John D (EVP, Chief Business Officer) | Sale | 5,842 | 52.52 | 306,792 |
| 2020-01-02 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 5,579 | 52.51 | 292,936 |
| 2019-12-13 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 11,853 | 50.28 | 595,968 |
| 2019-09-10 | Veness Adam M (VP, General Counsel and Sec.) | Sale | 824 | 45.47 | 37,463 |
| 2019-09-10 | Dable Habib J (CEO and President) | Sale | 5,625 | 45.44 | 255,571 |
| 2019-09-10 | Kumar Ravindra (SVP & Chief Scientific Officer) | Sale | 3,389 | 45.24 | 153,318 |
| 2019-09-10 | Quisel John D (EVP, Chief Business Officer) | Sale | 3,584 | 45.23 | 162,104 |
| 2019-09-10 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 8,000 | 45.52 | 364,160 |
| 2019-08-09 | Veness Adam M (VP, General Counsel and Sec.) | Sale | 3,268 | 45.00 | 147,060 |
| 2019-07-16 | Veness Adam M (VP, General Counsel and Sec.) | Sale | 538 | 40.71 | 21,901 |
| 2019-07-09 | Quisel John D (EVP, Chief Business Officer) | Option Ex | 8,908 | 5.43 | 48,343 |
| 2019-06-28 | George Jean (Director) | Sale | 11,812 | 41.17 | 486,300 |
| 2019-06-26 | George Jean (Director) | Sale | 25,688 | 39.16 | 1,005,942 |
| 2019-06-26 | George Jean (Director) | Option Ex | 37,500 | 27.42 | 1,028,137 |
| 2019-06-14 | Zakrzewski Joseph S | Buy | 5,000 | 38.05 | 190,250 |
| 2019-04-09 | Dable Habib J (CEO and President) | Sale | 7,460 | 44.76 | 333,931 |
| 2019-04-09 | Kumar Ravindra (SVP & Chief Scientific Officer) | Sale | 3,622 | 44.77 | 162,167 |
| 2019-04-09 | Quisel John D (EVP, CBO and Secretary) | Sale | 3,622 | 44.77 | 162,167 |
| 2019-04-09 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 12,000 | 45.03 | 540,420 |
| 2019-04-02 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 648 | 48.02 | 31,116 |
| 2019-01-18 | Celgene Corp /de/ | Buy | 706,206 | 43.00 | 30,366,858 |
| 2019-01-03 | Dable Habib J (CEO and President) | Sale | 1,957 | 42.15 | 82,487 |
| 2019-01-02 | Kumar Ravindra (SVP & Chief Scientific Officer) | Sale | 5,788 | 43.20 | 250,024 |
| 2019-01-02 | Quisel John D (EVP, CBO and Secretary) | Sale | 5,942 | 42.98 | 255,399 |
| 2019-01-02 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 5,712 | 43.10 | 246,210 |
| 2018-12-04 | Dable Habib J (CEO and President) | Sale | 12,675 | 53.06 | 672,535 |
| 2018-08-30 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 12,500 | 54.00 | 675,000 |
| 2018-08-30 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Option Ex | 12,500 | 27.97 | 349,625 |
| 2018-06-29 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 25,000 | 48.00 | 1,200,000 |
| 2018-06-29 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Option Ex | 25,000 | 24.11 | 602,750 |
| 2018-04-03 | Rovaldi Christopher (SVP, Program Mgmt and Ops) | Sale | 3,500 | 38.65 | 135,257 |
| 2018-04-03 | Kumar Ravindra (SVP & Chief Scientific Officer) | Sale | 1,203 | 38.75 | 46,616 |
| 2018-04-03 | Quisel John D (SVP, Corp. Dev., GC & Sec.) | Sale | 1,204 | 38.74 | 46,648 |
| 2018-04-03 | Sherman Matthew L (EVP & Chief Medical Officer) | Sale | 4,600 | 38.66 | 177,835 |
| 2018-04-03 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 4,000 | 38.66 | 154,620 |
| 2018-03-21 | Maniatis Tom | Option Ex | 18,750 | 5.08 | 95,250 |
| 2018-03-06 | Pops Richard F | Sale | 37,500 | 41.83 | 1,568,625 |
| 2018-03-06 | Pops Richard F | Option Ex | 37,500 | 5.08 | 190,500 |
| 2018-01-12 | Rovaldi Christopher (SVP, Program Mgmt and Ops) | Sale | 11,000 | 45.00 | 495,000 |
| 2018-01-12 | Rovaldi Christopher (SVP, Program Mgmt and Ops) | Option Ex | 11,000 | 24.11 | 265,210 |
| 2018-01-04 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 15,000 | 43.42 | 651,300 |
| 2018-01-03 | Rovaldi Christopher (SVP, Program Mgmt and Ops) | Sale | 833 | 42.45 | 35,360 |
| 2018-01-03 | Sherman Matthew L (EVP & Chief Medical Officer) | Sale | 4,633 | 42.20 | 195,498 |
| 2018-01-03 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Option Ex | 12,501 | 4.58 | 57,254 |
| 2018-01-02 | Rovaldi Christopher (SVP, Program Mgmt and Ops) | Sale | 1,433 | 42.41 | 60,773 |
| 2018-01-02 | Kumar Ravindra (SVP & Chief Scientific Officer) | Sale | 4,300 | 42.41 | 182,362 |
| 2018-01-02 | Quisel John D (SVP, Corp. Dev., GC & Sec.) | Sale | 4,333 | 42.42 | 183,805 |
| 2018-01-02 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 4,000 | 42.42 | 169,680 |
| 2017-12-15 | George Jean (Director) | Sale | 105,122 | 35.73 | 3,756,009 |
| 2017-09-28 | Kumar Ravindra (SVP & Chief Scientific Officer) | Option Ex | 6,761 | 5.28 | 35,698 |
| 2017-09-25 | Celgene Corp /de/ (10% Owner) | Buy | 745,592 | 37.00 | 27,586,904 |
| 2017-09-13 | Kumar Ravindra (SVP & Chief Scientific Officer) | Sale | 8 | 38.12 | 304 |
| 2017-09-13 | Quisel John D (SVP, Corp. Dev., GC & Sec.) | Sale | 8 | 38.03 | 304 |
| 2017-09-12 | Rovaldi Christopher (SVP, Program Mgmt and Ops) | Sale | 14,000 | 39.19 | 548,702 |
| 2017-09-12 | Kumar Ravindra (SVP & Chief Scientific Officer) | Sale | 5,105 | 38.85 | 198,329 |
| 2017-09-12 | Quisel John D (SVP, Corp. Dev., GC & Sec.) | Sale | 5,105 | 38.83 | 198,227 |
| 2017-09-12 | Sherman Matthew L (EVP & Chief Medical Officer) | Sale | 18,400 | 39.16 | 720,488 |
| 2017-09-12 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 16,000 | 39.11 | 625,808 |
| 2017-08-08 | Kumar Ravindra (SVP & Chief Scientific Officer) | Sale | 13,065 | 35.41 | 462,631 |
| 2017-08-08 | Kumar Ravindra (SVP & Chief Scientific Officer) | Option Ex | 13,065 | 24.11 | 314,997 |
| 2017-07-05 | Kumar Ravindra (SVP & Chief Scientific Officer) | Sale | 937 | 32.00 | 29,984 |
| 2017-07-05 | Kumar Ravindra (SVP & Chief Scientific Officer) | Option Ex | 937 | 7.12 | 6,671 |
| 2017-07-05 | Sherman Matthew L (EVP & Chief Medical Officer) | Sale | 16,000 | 32.00 | 512,000 |
| 2017-07-05 | Sherman Matthew L (EVP & Chief Medical Officer) | Option Ex | 8,000 | 7.12 | 56,960 |
| 2017-07-05 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 34,400 | 32.00 | 1,100,800 |
| 2017-07-05 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Option Ex | 21,900 | 6.20 | 135,780 |
| 2017-01-04 | Kumar Ravindra (SVP & Chief Scientific Officer) | Sale | 2,000 | 27.20 | 54,410 |
| 2017-01-04 | Quisel John D (SVP, Bus. Dev., GC & Secretary) | Sale | 1,700 | 27.00 | 45,891 |
| 2017-01-04 | Ertel Steven D (EVP & Chief Operating Officer) | Sale | 2,500 | 27.27 | 68,162 |
| 2017-01-04 | Sherman Matthew L (EVP & Chief Medical Officer) | Sale | 2,000 | 27.21 | 54,430 |
| 2017-01-04 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Sale | 1,700 | 27.25 | 46,325 |
| 2017-01-03 | Mclaughlin Kevin F (SVP, CFO and Treasurer) | Option Ex | 10,000 | 3.88 | 38,800 |
| 2016-12-30 | Zakrzewski Joseph S | Buy | 4,000 | 25.50 | 102,000 |
| 2016-12-22 | Kumar Ravindra (SVP & Chief Scientific Officer) | Option Ex | 14,561 | 4.58 | 66,689 |
| 2016-12-08 | Mcguire Terrance (Director) | Sale | 34,928 | 30.96 | 1,081,370 |
| 2016-12-07 | George Jean (Director) | Option Ex | 127,122 | 5.88 | 747,477 |
| 2016-11-17 | George Jean (Director) | Sale | 420,576 | 38.59 | 16,230,027 |
| 2016-11-16 | George Jean (Director) | Sale | 32,929 | 41.39 | 1,362,931 |
| 2016-11-09 | Knopf John L (CEO and President) | Sale | 100,000 | 32.19 | 3,219,000 |
| 2016-11-09 | Knopf John L (CEO and President) | Option Ex | 100,000 | 5.36 | 536,000 |
| 2016-10-10 | Kumar Ravindra (SVP & Chief Scientific Officer) | Sale | 16,833 | 34.14 | 574,678 |
| 2016-10-10 | Kumar Ravindra (SVP & Chief Scientific Officer) | Option Ex | 16,833 | 19.73 | 332,165 |
| 2016-10-07 | Kumar Ravindra (SVP & Chief Scientific Officer) | Sale | 19,644 | 33.69 | 661,708 |
| 2016-10-07 | Kumar Ravindra (SVP & Chief Scientific Officer) | Option Ex | 19,644 | 9.13 | 179,428 |
| 2016-10-06 | Kumar Ravindra (SVP & Chief Scientific Officer) | Sale | 16,009 | 34.65 | 554,631 |
| 2016-10-06 | Kumar Ravindra (SVP & Chief Scientific Officer) | Option Ex | 7,124 | 5.28 | 37,614 |
| 2016-09-30 | George Jean (Director) | Sale | 857,145 | 35.50 | 30,428,647 |
| 2016-09-21 | Quisel John D (SVP, Bus. Dev., GC & Secretary) | Sale | 45,952 | 38.05 | 1,748,473 |
| 2016-09-21 | Quisel John D (SVP, Bus. Dev., GC & Secretary) | Option Ex | 25,952 | 11.70 | 303,716 |
| 2016-09-12 | Quisel John D (SVP, Bus. Dev., GC & Secretary) | Sale | 21,438 | 32.14 | 689,017 |
Insider trading activities including stock purchases, stock sales, and option exercises of XLRN listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Acceleron Pharma Inc (symbol XLRN, CIK number 1280600) see the Securities and Exchange Commission (SEC) website.